Chmp 1A is a mediator of the anti-proliferative effects of All-trans Retinoic Acid in human pancreatic cancer cells

被引:27
|
作者
Li, Jing [1 ]
Orr, Brandon [1 ]
White, Kayla [1 ]
Belogortseva, Natalia [1 ]
Niles, Richard [1 ]
Boskovic, Goran
Nguyen, Hanh [1 ]
Dykes, Ava
Park, Maiyon [1 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Microbiol, Huntington, WV 25755 USA
来源
MOLECULAR CANCER | 2009年 / 8卷
关键词
IN-VITRO; BREAST-CANCER; CELLULAR RETINOL-BINDING-PROTEIN-1; PROTEIN EXPRESSION; FAMILIAL SYNDROME; BINDING PROTEINS; P53; DIFFERENTIATION; APOPTOSIS; CARCINOMA;
D O I
10.1186/1476-4598-8-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: We recently have shown that Charged multivesicular protein/Chromatin modifying protein1A (Chmp1A) functions as a tumor suppressor in human pancreatic tumor cells. Pancreatic cancer has the worst prognosis of all cancers with a dismal 5-year survival rate. Preclinical studies using ATRA for treating human pancreatic cancer suggest this compound might be useful for treatment of pancreatic cancer patients. However, the molecular mechanism by which ATRA inhibits growth of pancreatic cancer cells is not clear. The objective of our study was to investigate whether Chmp1A is involved in ATRA-mediated growth inhibition of human pancreatic tumor cells. Results: We performed microarray studies using HEK 293T cells and discovered that Chmp1A positively regulated Cellular retinol-binding protein 1 (CRBP-1). CRBP-1 is a key regulator of All-trans retinoic acid ( ATRA) through ATRA metabolism and nuclear localization. Since our microarray data indicates a potential involvement of Chmp1A in ATRA signaling, we tested this hypothesis by treating pancreatic tumor cells with ATRA in vitro. In the ATRA-responsive cell lines, ATRA significantly increased the protein expression of Chmp1A, CRBP-1, P53 and phospho-P53 at serine 15 and 37 position. We found that knockdown of Chmp1A via shRNA abolished the ATRA-mediated growth inhibition of PanC-1 cells. Also, Chmp1A silencing diminished the increase of Chmp1A, P53 and phospho-P53 protein expression induced by ATRA. In the ATRA non-responsive cells, ATRA did not have any effect on the protein level of Chmp1A and P53. Chmp1A over-expression, however, induced growth inhibition of ATRA non-responsive cells, which was accompanied by an increase of Chmp1A, P53 and phospho-P53. Interestingly, in ATRA responsive cells Chmp1A is localized to the nucleus, which became robust upon ATRA treatment. In the ATRA-non-responsive cells, Chmp1A was mainly translocated to the plasma membrane upon ATRA treatment. Conclusion: Collectively our data provides evidence that Chmp1A mediates the growth inhibitory activity of ATRA in human pancreatic cancer cells via regulation of CRBP-1. Our results also suggest that nuclear localization of Chmp1A is important in mediating ATRA signaling.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
    Buteyn, Nathaniel J.
    Fatehchand, Kavin
    Santhanam, Ramasamy
    Fang, Huiqing
    Dettorre, Gino M.
    Gautam, Shalini
    Harrington, Bonnie K.
    Henderson, Sally E.
    Merchand-Reyes, Giovanna
    Mo, Xiaokui
    Benson, Don M.
    Carson, William E., III
    Vasu, Sumithira
    Byrd, John C.
    Butchar, Jonathan P.
    Tridandapani, Susheela
    INTERNATIONAL IMMUNOLOGY, 2018, 30 (08) : 375 - 383
  • [42] All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis
    Mei, Dan
    Lv, Bin
    Chen, Bo
    Xiao, Shan
    Jiang, Jie
    Xie, Yan
    Jiang, Ling
    PLOS ONE, 2017, 12 (08):
  • [43] Anti-proliferative actions of N′-desmethylsorafenib in human breast cancer cells
    Cui, Pei H.
    Rawling, Tristan
    Gillani, Tina B.
    Bourget, Kirsi
    Wang, Xiao-Suo
    Zhou, Fanfan
    Murray, Michael
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (03) : 419 - 427
  • [44] All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer
    Zhang, Yang
    Guan, Dong-xian
    Shi, Jie
    Gao, Hong
    Li, Jing-jing
    Zhao, Jiang-sha
    Qiu, Lin
    Liu, Jiang
    Li, Nan
    Guo, Wei-xing
    Xue, Jie
    Zhou, Fei-guo
    Wu, Meng-chao
    Wang, Hong-yang
    Xie, Dong
    Cheng, Shu-qun
    JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1255 - 1263
  • [45] Lupeol synergizes with doxorubicin to induce anti-proliferative and apoptotic effects on breast cancer cells
    Malekinejad, Faezeh
    Kheradmand, Fatemeh
    Khadem-Ansari, Mohammad Hassan
    Malekinejad, Hassan
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (01) : 103 - 115
  • [46] Proteomic analysis of changes in the protein composition of MCF-7 human breast cancer cells induced by all-trans retinoic acid, 9-cis retinoic acid, and their combination
    Flodrova, D.
    Benkovska, D.
    Macejova, D.
    Bialesova, L.
    Hunakova, L.
    Brtko, J.
    Bobalova, J.
    TOXICOLOGY LETTERS, 2015, 232 (01) : 226 - 232
  • [47] Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
    Bouriez, Damien
    Giraud, Julie
    Gronnier, Caroline
    Varon, Christine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [48] Anti-proliferative effects of beta-blocker propranolol on human lung cancer and noncancer cells
    Terzi, Menderes Yusuf
    Urhan-kucuk, Meral
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2023, 124 (04): : 292 - 303
  • [49] Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells
    Cristiano, Maria Chiara
    Cosco, Donato
    Celia, Christian
    Tudose, Andra
    Mare, Rosario
    Paolino, Donatella
    Fresta, Massimo
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2017, 150 : 408 - 416
  • [50] Combating metastasis of breast cancer cells with a carboplatin analogue containing an all-trans retinoic acid ligand
    Dai, Yi
    Huang, Hai
    Zhu, Yang
    Cheng, Junjie
    Shen, Ai-Zong
    Liu, Yangzhong
    DALTON TRANSACTIONS, 2020, 49 (16) : 5039 - 5043